Form 4: TG Therapeutics Director Sells Shares for Tax Obligations

TG Therapeutics Director Sagar Lonial sold 20,852 shares of common stock to cover tax liabilities, retaining 94,061 shares.

Summary

• Director Sagar Lonial of TG Therapeutics, Inc. (TGTX) sold 20,852 shares of common stock.
• The transaction occurred on September 11, 2025, at a volume-weighted average price of $32.24 per share.
• The sale was executed by the company's restricted stock administrator to satisfy Lonial's income tax obligations.
• Following the sale, Lonial beneficially owns 94,061 shares, which include restricted common stock vesting over various time periods.

Sentiment

Score: 5

Explanation: The transaction is a routine sale to cover tax obligations on restricted stock, not indicative of a change in sentiment towards the company's prospects or a significant event for the company's valuation.

Future Outlook

N/A

Industry Context

N/A

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine tax-related sale by a director, not a discretionary sale indicating a change in confidence.

Key Dates

Recommendation

The sale of shares by Director Lonial is explicitly for tax obligations related to restricted stock, a common and often pre-planned event. It does not reflect a change in the company's fundamentals or the director's long-term view, thus a 'hold' recommendation is appropriate based solely on this filing.

Keywords

TGTX, TG Therapeutics, Sagar Lonial, Insider Trading, Form 4, Stock Sale, Director, Beneficial Ownership